专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20140322344A1 VACCINE PREPARATION FOR CANCER TREATMENT 审中-公开
标题翻译：用于癌症治疗的疫苗制剂
公开(公告)号：US20140322344A1
公开(公告)日：2014-10-30
申请号：US14241321
申请日：2012-08-30
申请人： Hiroshi Shiku , Naozumi Harada , Daisuke Muraoka , Kazunari Akiyoshi
发明人： Hiroshi Shiku , Naozumi Harada , Daisuke Muraoka , Kazunari Akiyoshi
IPC分类号： A61K39/385 , A61K39/39
CPC分类号： A61K39/385 , A61K39/0011 , A61K45/06 , A61K47/61 , A61K2039/55511 , A61K2039/55561 , A61K2039/6087 , C07K14/4748 , C07K2319/00 , C07K2319/40 , C12N15/117 , C12N2310/17 , A61K2300/00
摘要： A vaccine preparation for treating cancer includes a complex of a hydrophobized polysaccharide and at least one synthetic long peptide derived from a tumor-specific antigenic protein and/or a pathogen-derived antigenic protein. The at least one synthetic long peptide contains at least one CD8+ cytotoxic T-cell recognition epitope and at least one CD4+ helper T-cell recognition epitope. The complex is simultaneously administered to the patient with at least one immunopotentiating agent.
摘要翻译：用于治疗癌症的疫苗制剂包括疏水化多糖和衍生自肿瘤特异性抗原蛋白和/或病原体衍生抗原蛋白的至少一种合成长肽的复合物。所述至少一种合成长肽含有至少一种CD8 +细胞毒性T细胞识别表位和至少一种CD4 +辅助T细胞识别表位。使用至少一种免疫增强剂将复合物同时施用于患者。

2. 发明申请

US20110318839A1 METHOD FOR ENHANCING A FUNCTION OF A T CELL 有权
标题翻译：增强细胞功能的方法
公开(公告)号：US20110318839A1
公开(公告)日：2011-12-29
申请号：US13254602
申请日：2010-03-05
申请人： Hiroshi Shiku , Hiroaki Ikeda , Koichi Iwamura , Junichi Mineno , Ikunoshin Kato
发明人： Hiroshi Shiku , Hiroaki Ikeda , Koichi Iwamura , Junichi Mineno , Ikunoshin Kato
IPC分类号： C12N5/0783
CPC分类号： A61K35/17 , A61K2035/124 , A61K2039/5158 , C12N5/0636 , C12N15/113 , C12N2310/14 , C12N2501/48 , C12N2501/599 , C12N2310/531
摘要： Disclosed is a method for enhancing the function of a T cell, which is characterized by inhibiting the expression of programmed death-1 ligand 1 (PD-L1) and/or programmed death-1 ligand 2 (PD-L2) in the T cell. Also disclosed is a function-enhanced T cell which is produced by the function enhancement method. Further disclosed is a therapeutic agent comprising the function-enhanced T cell. The T cell can enhance an immune response to cancer, and is useful in an immunotherapy effective for cancer and the treatment or prevention of infectious diseases and autoimmune diseases.
摘要翻译：公开了一种增强T细胞功能的方法，其特征在于抑制T细胞中程序性死亡-1配体1（PD-L1）和/或程序性死亡-1配体2（PD-L2）的表达。还公开了通过功能增强方法产生的功能增强T细胞。还公开了包含功能增强T细胞的治疗剂。 T细胞可以增强对癌症的免疫应答，并且可用于对癌症有效的免疫治疗和治疗或预防感染性疾病和自身免疫性疾病。

3. 发明授权

US07414032B2 Vaccine comprising a polynucleotide encoding an antigen recognized by a CD4+ helper T-cell and a polynucleotide encoding a tumor specific or associated antigen recognized by a CD8+ CTL 有权
标题翻译：包含编码由CD4 +辅助T细胞识别的抗原的多核苷酸和编码由CD8 + CTL识别的肿瘤特异性或相关抗原的多核苷酸的疫苗
公开(公告)号：US07414032B2
公开(公告)日：2008-08-19
申请号：US10746747
申请日：2003-12-23
申请人： Hiroshi Shiku
发明人： Hiroshi Shiku
IPC分类号： A01K43/04 , A61K31/70
CPC分类号： A61K39/0011 , A61K2039/53 , A61K2300/00
摘要： The present invention relates to a DNA vaccine for developing tumor-specific immunity. Specifically, the invention relates to a DNA vaccine comprising antigens recognized by CD4+ helper T cells and CD8+ cytotoxic T cells, respectively. Preferably, the antigen recognized by CD4+ helper T cells is a molecule identified by the SEREX method and that recognized by CD8+ cytotoxic T cells is a tumor-specific antigen, tumor-associated antigen or cell-associated antigen. Furthermore, so that the antigens recognized by CD4+ helper T cells and CD8+ CTL are expressed and presented on the same cell, the expression vectors preferably are immobilized on the same gold particle and administered into the cell by gene gun; however, this invention is not restricted thereto. The vaccine can also be used as a pharmaceutical agent.
摘要翻译：本发明涉及用于发展肿瘤特异性免疫的DNA疫苗。具体地，本发明涉及分别包含被CD4 +辅助T细胞和CD8 +细胞毒性T细胞识别的抗原的DNA疫苗。优选地，由CD4 +辅助T细胞识别的抗原是通过SEREX方法鉴定的分子，并且被CD8 +细胞毒性T细胞识别的是肿瘤特异性抗原，肿瘤相关抗原或细胞相关抗原。此外，使得由CD4 +辅助T细胞和CD8 + CTL识别的抗原被表达并存在于相同的细胞上，表达载体优选固定在相同的金颗粒并通过基因枪施用于细胞; 然而，本发明不限于此。疫苗也可以用作药剂。

4. 发明申请

US20060182721A1 Method of preparing langerhans cell from cd14-positive cell being human peripheral blood mononuclear cell with use of notch ligand delta-1, gm-csf and tgf-ss 审中-公开
标题翻译：使用缺口配体delta-1，gm-csf和tgf-ss从CD14阳性细胞制备朗格汉斯细胞的方法是人外周血单核细胞
公开(公告)号：US20060182721A1
公开(公告)日：2006-08-17
申请号：US10565273
申请日：2004-07-22
申请人： Naoyuki Katayama , Koshi Oishi , Hiroshi Shiku
发明人： Naoyuki Katayama , Koshi Oishi , Hiroshi Shiku
IPC分类号： A61K35/12 , C12N5/08
CPC分类号： C12N5/0639 , A61K2035/124 , C12N2501/15 , C12N2501/22 , C12N2501/42
摘要： This invention provides a method for preparing Langerhans cells from CD14-positive cells, which are human peripheral blood mononuclear cells. This method comprises culturing human peripheral blood mononuclear cells in the presence of Notch ligand, GM-CSF, and TGF-β.
摘要翻译：本发明提供了作为人外周血单核细胞的CD14阳性细胞制备朗格汉斯细胞的方法。该方法包括在Notch配体，GM-CSF和TGF-β的存在下培养人外周血单核细胞。

5. 发明授权

US09243227B2 Cytotoxic T lymphocyte 有权
公开(公告)号：US09243227B2
公开(公告)日：2016-01-26
申请号：US13431542
申请日：2012-03-27
申请人： Hiroshi Shiku , Atsunori Hiasa , Satoshi Okumura , Hiroaki Naota , Yoshihiro Miyahara
发明人： Hiroshi Shiku , Atsunori Hiasa , Satoshi Okumura , Hiroaki Naota , Yoshihiro Miyahara
IPC分类号： C12N5/00 , C12N5/0783 , A61K39/00 , A61K48/00
CPC分类号： C12N5/0636 , A61K39/00 , A61K39/0011 , A61K48/00 , A61K2039/5154 , A61K2039/5156
摘要： The present invention relates to a T lymphocyte having an activity to induce a T lymphocyte recognizing an antigen and a technique to use the T lymphocyte.

6. 发明申请

US20110250230A1 CELL CAPABLE OF EXPRESSING EXOGENOUS GITR LIGAND 有权
标题翻译：能表达外源GITR配体的电池
公开(公告)号：US20110250230A1
公开(公告)日：2011-10-13
申请号：US13062999
申请日：2009-09-11
申请人： Hiroshi Shiku , Hiroaki Ikeda , Jun Mitsui , Yuki Takenaka , Junichi Mineno , Ikunoshin Kato
发明人： Hiroshi Shiku , Hiroaki Ikeda , Jun Mitsui , Yuki Takenaka , Junichi Mineno , Ikunoshin Kato
IPC分类号： A61K39/00 , C12N15/63 , A61P35/00 , C12N5/10
CPC分类号： A61K39/0005 , A61K35/12 , A61K38/00 , A61K38/191 , A61K39/0011 , A61K2039/5152 , A61K2039/5156 , C07K14/70575 , C07K2319/30 , C12N2799/022 , C12N2799/027
摘要： Disclosed are: a cell capable of expressing an exogenous GITRL or an exogenous GITRL derivative; a method for producing the cell; a therapeutic or prophylactic agent comprising the cell as an active ingredient; use of the cell in the manufacture of a therapeutic or prophylactic agent; a method comprising a step of administering the cell to a subject; a viral vector carrying a gene encoding a GITRL or a GITRL derivative; a therapeutic or prophylactic agent comprising the viral vector as an active ingredient; use of the viral vector in the manufacture of a therapeutic or prophylactic agent; and a method comprising a step of administering the viral vector to a subject.
摘要翻译：公开了能够表达外源GITRL或外源性GITRL衍生物的细胞; 电池的制造方法; 包含该细胞作为活性成分的治疗或预防剂; 在制造治疗或预防剂中使用细胞; 一种方法，包括将细胞施用于受试者的步骤; 携带编码GITRL或GITRL衍生物的基因的病毒载体; 包含病毒载体作为活性成分的治疗或预防剂; 病毒载体在制备治疗或预防药物中的应用; 以及包括将病毒载体施用于受试者的步骤的方法。

7. 发明申请

US20090324566A1 T-Cell Receptor and Nucliec Acid Encoding the Receptor 有权
标题翻译： T细胞受体和编码受体的核糖酸
公开(公告)号：US20090324566A1
公开(公告)日：2009-12-31
申请号：US11991964
申请日：2006-09-07
申请人： Hiroshi Shiku , Atsunori Hiasa , Satoshi Okumura , Hiroaki Naota , Yoshihiro Miyahara
发明人： Hiroshi Shiku , Atsunori Hiasa , Satoshi Okumura , Hiroaki Naota , Yoshihiro Miyahara
IPC分类号： A61K45/00 , C07K14/00 , C07K16/00 , C07H21/00 , C12N15/74 , C12N5/10 , A61K31/7088 , A61P35/00
CPC分类号： C07K14/705 , A61K35/12 , A61K38/00 , C07K14/7051 , C12N5/0636 , C12N2501/515 , C12N2510/00
摘要： A polypeptide comprising a polypeptide consisting of an amino acid sequence shown in SEQ ID NO: 5 of Sequence Listing or a polypeptide consisting of an amino acid sequence having deletion, addition, insertion or substitution of one to several amino acid residues in the sequence, the polypeptide being capable of constituting an HLA-A24-restricted, MAGE-A4143-151-specific T cell receptor together with a polypeptide consisting of an amino acid sequence shown in SEQ ID NO: 2 of Sequence Listing.
摘要翻译：一种多肽，其包含由序列表的SEQ ID NO：5所示的氨基酸序列组成的多肽或由序列中一至数个氨基酸残基的缺失，添加，插入或取代的氨基酸序列组成的多肽，能够构成HLA-A24限制性MAGE-A4143-151特异性T细胞受体的多肽以及由序列表的SEQ ID NO：2所示的氨基酸序列组成的多肽。

8. 发明申请

US20060121029A1 Method and composition for regulating the activity of regulatory t cells 审中-公开
标题翻译：用于调节调节性T细胞活性的方法和组成
公开(公告)号：US20060121029A1
公开(公告)日：2006-06-08
申请号：US10525145
申请日：2002-08-30
申请人： Hiroshi Shiku
发明人： Hiroshi Shiku
IPC分类号： A61K39/395
CPC分类号： A61K38/1709 , A61K38/16 , A61K38/179 , A61K38/20 , A61K38/208 , A61K38/217 , A61K38/53 , A61K39/001 , A61K48/00 , A61K2039/5158 , A61K2039/53 , A61K2039/55527 , A61K2039/55538 , A61K2300/00
摘要： The present invention provides a composition and method of regulating the activity of regulatory T cells. The present invention relates to a composition containing an antigen recognized by CD4+CD25+ regulatory T cells or an expression vector encoding such an antigen and a method of controlling an immune response from a mammal by administrating the composition to the mammal. Furthermore, the present invention provides effective means for suppressing a rejection reaction and a graft-versus-host reaction in transplantation and for prevention and treatment of an autoimmune disease or an allergic disease. Furthermore, an immunosuppression condition can be removed by the administration of Interferon-γ or a combination of Interleukin 12 and Interleukin 18. In other words, those cytokine actions and the sensitization with an SEREX antigen are suitably combined to artificially manipulate regulatory T cells, allowing the cells to be applied to an autoimmune disease, reactions accompanied with organ transplantation, allergic reaction, control of tumor immunity, and the like.
摘要翻译：本发明提供调节T细胞活性的组合物和方法。本发明涉及包含由CD4 + / CD25 +调节性T细胞识别的抗原或编码这种抗原的表达载体的组合物和控制免疫应答的方法哺乳动物通过将该组合物施用于哺乳动物。此外，本发明提供抑制移植中的排斥反应和移植物抗宿主反应以及预防和治疗自身免疫性疾病或过敏性疾病的有效手段。此外，可以通过施用干扰素-γ或白细胞介素12和白细胞介素18的组合来消除免疫抑制状况。换句话说，这些细胞因子作用和用SEREX抗原的敏化被适当地组合以人工操纵调节性T细胞，允许应用于自身免疫性疾病的细胞，伴随器官移植的反应，过敏反应，肿瘤免疫力的控制等。

9. 发明申请

US20060073126A1 Cytotoxic T lymphocyte 审中-公开
标题翻译：细胞毒T淋巴细胞
公开(公告)号：US20060073126A1
公开(公告)日：2006-04-06
申请号：US11171365
申请日：2005-07-01
申请人： Hiroshi Shiku , Atsunori Hiasa , Satoshi Okumura , Hiroaki Naota , Yoshihiro Miyahara
发明人： Hiroshi Shiku , Atsunori Hiasa , Satoshi Okumura , Hiroaki Naota , Yoshihiro Miyahara
IPC分类号： A61K48/00 , A61K39/00 , C12N5/08
CPC分类号： C12N5/0636 , A61K39/00 , A61K39/0011 , A61K48/00 , A61K2039/5154 , A61K2039/5156
摘要： The present invention relates to a T lymphocyte having an activity to induce a T lymphocyte recognizing an antigen and a technique to use the T lymphocyte.
摘要翻译：本发明涉及具有诱导T淋巴细胞识别抗原的活性的T淋巴细胞和使用T淋巴细胞的技术。

10. 发明授权

US09181525B2 Method for enhancing a function of a T cell 有权
标题翻译：增强T细胞功能的方法
公开(公告)号：US09181525B2
公开(公告)日：2015-11-10
申请号：US13254602
申请日：2010-03-05
申请人： Hiroshi Shiku , Hiroaki Ikeda , Koichi Iwamura , Junichi Mineno , Ikunoshin Kato
发明人： Hiroshi Shiku , Hiroaki Ikeda , Koichi Iwamura , Junichi Mineno , Ikunoshin Kato
IPC分类号： C12N15/00 , C12N15/11 , C12N5/0783 , A61K35/17 , C12N15/113 , A61K35/12 , A61K39/00
CPC分类号： A61K35/17 , A61K2035/124 , A61K2039/5158 , C12N5/0636 , C12N15/113 , C12N2310/14 , C12N2501/48 , C12N2501/599 , C12N2310/531
摘要： Disclosed is a method for enhancing the function of a T cell, which is characterized by inhibiting the expression of programmed death-1 ligand 1 (PD-L1) and/or programmed death-1 ligand 2 (PD-L2) in the T cell. Also disclosed is a function-enhanced T cell which is produced by the function enhancement method. Further disclosed is a therapeutic agent comprising the function-enhanced T cell. The T cell can enhance an immune response to cancer, and is useful in an immunotherapy effective for cancer and the treatment or prevention of infectious diseases and autoimmune diseases.
摘要翻译：公开了一种增强T细胞功能的方法，其特征在于抑制T细胞中程序性死亡-1配体1（PD-L1）和/或程序性死亡-1配体2（PD-L2）的表达。还公开了通过功能增强方法产生的功能增强T细胞。还公开了包含功能增强T细胞的治疗剂。 T细胞可以增强对癌症的免疫应答，并且可用于对癌症有效的免疫治疗和治疗或预防感染性疾病和自身免疫性疾病。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式